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Background. Gastroesophageal reﬂux disease is a common condition with increasing prevalence worldwide. The disease
encompasses a broad spectrum of clinical symptoms and disorders from simple heartburn without esophagitis to erosive
esophagitis with severe complications, such as esophageal strictures and intestinal metaplasia. Diagnosis is based mainly on
ambulatory esophageal pH testing and endoscopy. There has been a long-standing debate about the best treatment approach
for this troublesome disease. Methods and Results. Medical treatment with PPIs has an excellent eﬃcacy in reversing the symptoms
of GERD, but they should be taken for life, and long-term side eﬀects do exist. However, patients who desire a permanent cure and
have severe complications or cannot tolerate long-term treatment with PPIs are candidates for surgical treatment. Laparoscopic
antireﬂux surgery achieves a signiﬁcant symptom control, increased patient satisfaction, and complete withdrawal of antireﬂux
medications, in the majority of patients. Conclusion. Surgical treatment should be reserved mainly for young patients seeking
permanent results. However, the choice of the treatment schedule should be individualized for every patient. It is up to the patient,
the physician and the surgeon to decide the best treatment option for individual cases.
Copyright © 2009 Theodore Liakakos et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Gastroesophageal reﬂux disease (GERD), recognized as a
clinical entity only in the mid-1930s, is now the most
common upper gastrointestinal disease in the Western
countries, with 10%–20% of the population experiencing
weekly symptoms [1–4]. Its prevalence is also increasing
in the Far East (Japan) and other areas in Asia [5, 6].
This may be related to increased fat consumption in the
diet, and the expanding proportion of obese individuals
[7, 8].
The disease is characterized by a broad spectrum of clin-
ical symptoms and disorders [9]. According to the Montreal
deﬁnition and classiﬁcation of the disease [10], GERD is a
condition which develops when the reﬂux of stomach con-
tents causes troublesome symptoms and/or complications.
The disease encompasses esophageal and extra-esophageal
syndromes. The esophageal syndromes include the symp-
tomatic syndromes, that is, the typical reﬂux syndrome and
t h er e ﬂ u xc h e s tp a i ns y n d r o m e , and the syndromes with
esophageal injury, that is, reﬂux esophagitis, reﬂux stricture,
Barrett’s esophagus (BE) and esophageal adenocarcinoma.T h e
extra-esophageal syndromes are respiratory conditions, such
as chronic coughing, asthma, laryngitis, otitis media, mainly
caused by the reﬂux of gastric juice into the respiratory tract
[11].
GERD is a chronic disease characterized mainly by
symptoms of heartburn and acid regurgitation during daily
activities. In addition approximately 45% of the symp-
tomatic GERD suﬀerers have nighttime symptoms (NTG),
and patients with NTG have signiﬁcantly greater odds of
having moderate or severe GERD [12]. The aim of therapy
for patients with GERD is to achieve symptomatic relief,
prevention of relapses and healing in patients with severe
esophagitis or complicated disease. These goals can now be
achieved with medication, such as proton-pump inhibitors
(PPI), which are now the mainstay of medical treatment
of GERD. On the other hand, antireﬂux surgery, open or2 Gastroenterology Research and Practice
laparoscopic, has been eﬀectively used for long-term control
of the disease [13].
In this review we will try to compare the beneﬁts and
drawbacks of both medical and surgical treatment and
present the main indications for both options in the man-
agement of GERD.
2.NaturalHistory
The natural history of GERD has not been well clariﬁed yet
[14] .N a t u r a lh i s t o r ys t u d i e si nG E R Da r eu s u a l l yr e t r o s p e c -
tiveandcommonlyaﬄictedwithaplethoraofshortcomings.
Two diﬀerent concepts have been proposed for the natural
history of GERD. The traditional concept approaches the
disease as a spectrum, emphasizing the potential progress
over time of patients along the spectrum [15, 16]. On the
mild end of the spectrum is patients with nonerosive reﬂux
disease (NERD) and on the severe end are patients with
complicated GERD (erosive esophagitis, stricture, Barrett’s
esophagus) [17]. This conceptual framework focused on
esophageal mucosal injury as the most signiﬁcant clinical
outcome in GERD. A recent large prospective cohort study
conﬁrms this concept, showing that true progression from
mild to severe disease and even to BE has occurred over 2
y e a r sf o l l o wu p[ 17].
In contrast, a new concept indicates that GERD is a
categorical disease with three distinct entities: NERD, erosive
esophagitis,a n dBarrett’s esophagus. These three phenotypes
represent diﬀerent disorders and movement among them is
limited, suggesting that those once determined remain true
to form [5, 18, 19]. After discontinuing treatment reﬂux
symptoms tend to recur; however, patients within one of
the 3 distinct entities will relapse in the same entity and
not to any of the other two. This conceptual framework
swifts our focus from mucosal injury to mechanisms leading
to symptom generation. A large study with an average of
7.6 years monitoring observed that GERD usually does not
progress over the time [20]. According to this report, GERD
is a chronic disease but not progressive; reﬂux symptoms
tend to recur but the endoscopic ﬁndings do not progress
in most patients. After discontinuing treatment, patients
within one of the 3 dinstict entities will relapse in the
same entity and not to any of the other two. However,
other studies conﬁrm that progression of NERD to erosive
esophagitis is possible in only 10% of GERD patients. The
other patients remain within their respective phenotypic
presentations [21].
Patients with severe esophagitis are at especially high
risk of developing a stricture. One % per year of these
patients develops a stricture, which is usually a direct result
of interrupted acid suppressive therapy [20]. Long-standing
reﬂux symptoms are a major risk factor for the development
of BE. In these patients prolonged acid and perhaps alkaline
injury leads to a signiﬁcant change of esophageal mucosa
from its squamous epithelium to a columnar conﬁguration.
Moreover, abnormalities in esophageal peristalsis and gastric
dysmotility are other factors which may play a signiﬁcant
role in the pathogenesis of BE. Often failure of symptoms to
resolve with acid-reducing medication may be attributed to
the presence of duodenal contents in the reﬂuxate causing an
unablatedinjurytotheesophaguswithitsassociatedmotility
abnormalities [22]. Patients with BE have an increased risk
of esophageal adenocarcinoma; actually the incidence of
adenocarcinoma in these patients is 40 times greater than
that in the general population. In addition, almost 10% of
patients with BE have coexistent adenocarcinoma at the time
of initial endoscopy [23].
3.Pathophysiology
In the lower part of the esophagus, lies a zone of increased
pressure, the lower esophageal sphincter (LES), which has
as a primary role to prevent reﬂux of gastric chyme into
the esophagus. Factors contributing to this are the intrinsic
musculature of the distal esophagus, the sling ﬁbers of the
cardia, the crura of the diaphragm, and the intraabdominal
pressure [24, 25].
The LES relaxes in response to esophageal peristalsis
to allow the passage of bolus into the stomach. Transient
lower esophageal sphincter relaxations (TLESRs) are visceral
reﬂexes occurring mainly in response to gastric distension,
and their frequency is inﬂuenced by foods and smoking.
From a therapeutic perspective, GERD is a disorder of both
motility and esophageal acid exposure. Motility mechanisms
include transient lower esophageal sphincter relaxations
(TLESRs), lower esophageal pressure abnormalities (includ-
ing the presence of hiatal hernia), impaired esophageal
peristalsis, and delayed gastric emptying. Among these
motility abnormalities, TLESRs are thought to be a leading
one. In patients with GERD, TLESRs account for 50%–75%
of reﬂux episodes especially in patients with postprandial or
upright reﬂux [26–29]. In contrast, in patients with mainly
supine reﬂux the LES becomes incompetent and the role of
TLESRs decreases [28].
According to the classical view of GERD, acid reﬂux
(nadir pH <4) is considered the most important component
in the pathogenesis of this disease, based on the induction
of heartburn during perfusion of the esophagus with acidic
solutions [30]. However, current evidence using the mul-
tichannel impedance with pH sensor suggests that weakly
acidic events (nadir pH between 4 and 7) in the esophagus
are associated with classic GERD symptoms, particularly
in patients taking proton pump inhibitors (PPIs) [31, 32].
In addition, studies using bilirubin monitoring together
with pH monitoring showed a synergism between acid and
bile reﬂux components in determining esophageal mucosal
damage [33, 34].
GERD is often associated with a hiatal hernia, especially
a sliding hiatal hernia (Type I hernia). In this type of hernia
thecardiaofthestomachisallowedtomigratebackandforth
betweentheposteriormediastinumandtheperitonealcavity.
Therefore, the gastroesophageal junction is incompetent and
large volumes of gastric contents pass unimpeded into the
hiatal sac; furthermore the larger the size of the hernia, the
greater the risk of abnormal reﬂux [35, 36].
Helicobacter pylori (H. pylori) infection has also been
implicated in the pathogenesis of GERD. H. pylori infection
maybeassociatedwitheitherincreasedacidsecretion[37]orGastroenterology Research and Practice 3
achlorydria with resultant atrophic gastritis [38], depending
on the species of the bacterium and the inﬂammatory
response induced [8]. Observations showing that H. pylori
negative patients present with more severe esophagitis than
H. pylori positive ones, suggest that this organism may have
ap r o t e c t i v er o l ei nG E R D[ 39]. Indeed, infection by these
bacteria may induce atrophy and a reduction in gastric acid
production, resulting in lower risk of development of GERD.
In contrast, eradication of H. pylori infection may result
in a return to normal acid production and exacerbation
of GERD [40]. However, more recent clinical research
could not ﬁnd suﬃc i e n te v i d e n c ef o rap o s s i b l er o l eo fH .
pylori infection in the development of GERD and erosive
esophagitis [41]. In clinical practice though, since chronic H.
pylori infection is associated with an increased risk for peptic
ulceration and gastric cancer, current guidelines recommend
H. pylori eradication irrespective of potential eﬀects on
GERD [42].
4.DiagnosticMethodology
Although many tools are available for diagnosis of GERD,
such as endoscopy, manometry, ambulatory pH monitoring,
and esophagogram, none of them is considered the gold
standard. Herein, the utility and clinical applications of each
test will be analyzed.
Upper gastrointestinal endoscopy is one of the principal
tests used and its main use in patients with GERD is
the evaluation of treatment failures and risk manage-
ment. Endoscopy may detect esophageal mucosal injury
due to GERD (erosive esophagitis, ulceration, stricture,
Barrett’s esophagus). The endoscopists are directed to grade
esophageal mucosal breaks with esophagitis according to
the Los Angeles Classiﬁcation of Esophagitis in 1996 [43].
Typical esophagitis is essential for the diagnosis of GERD
[43]. The identiﬁcation of esophagitis is highly speciﬁc
(90%–95%) for GERD, but the endoscopy has a quit low
sensitivity mainly because the majority of symptomatic
GERD patients will have no evidence of mucosal injuries
[44]. In clinical practice endoscopy is used as a screening
test for BE esophagus or esophageal carcinoma in patients
with chronic GERD [45, 46]. Thus, all patients ≥50 years of
age with 5–10 years of heartburn should perform endoscopic
screening for BE and dysplasia. Endoscopy may also play a
main role in the concept of “alarm symptoms”, although a
recent meta-analysis showed that they performed poorly as
diagnostic tests. Proposed alarm symptoms include vomit-
ing, weight loss, dysphagia, anemia, signs of gastrointestinal
blood loss, chest pain, or epigastric mass [47]. Among them
dysphagia and especially troublesome dysphagia warrants
endoscopic evaluation because it can be indicative of a
stricture or malignancy. Moreover, in GERD patients with
dysphagia without obvious obstructing lesion the potential
value of endoscopy with esophageal biopsies increases as
eosinophilic esophagitis is recognized as a confounding
clinical entity [48] .T h e r ei sn oe v i d e n c et os u p p o r tt h e
utility of routine esophageal biopsies in patients with reﬂux
symptoms without dysphagia [49].
In patients with persistent reﬂux symptoms despite
PPI therapy and normal ﬁndings on endoscopy a fur-
ther evaluation is recommended in order to establish the
diagnosis of GERD or to identify alternative diagnoses,
such as motor esophageal abnormalities (mainly achalasia),
functional heartburn, or eosinophilic esophagitis. Thus,
manometry should be the second diagnostic test in order
to evaluate peristaltic function and diagnose achalasia. This
test helps to analyze the function of the peristaltic activity
of the body of the esophagus and the LES, prior to anti-
reﬂuxsurgery.NormalpressuresattheLESrangebetween12
and 30mmHg. A mechanically defective sphincter is deﬁned
as having one of the following characteristics: an average
resting pressure of less than 6mmHg, an average length of
less than 2cm or an average length exposed to the positive-
pressure environment of the abdominal cavity of less than
1cm [50]. However, according to the American Gastroen-
terologicalAssociationrecommendations[51]mano metryis
not indicated for conﬁrming a suspected diagnosis of GERD.
It is mainly used to establish the diagnosis of dysphagia
in cases in which a mechanical obstruction (e.g., stricture)
cannot be found. It is also indicated for the preoperative
assessment of candidates for antireﬂux surgery, to exclude
achalasia or ineﬀective peristalsis (<30mmHg) [52]. In
combination with impedance, manometry helps to identify
patients with a signiﬁcant defect in motility disorders,
such as achalasia or aperistalsis associated with collagen
disease, such as scleroderma [53]. Recent studies showed
that high-resolution manometry has a better sensitivity in
recognizing atypical pattern of esophageal motor disorders
[54]. Moreover, manometry serves to localize the LES for
subsequent pH monitoring for documentation of abnormal
esophageal acid exposure.
The best method to diagnose acid reﬂux is the 24-
hour pH test [2]. Acid reﬂux episodes are deﬁned as a
pH fall <4. An overall score, known as DeMeester score,
is calculated using a special formula; this value should
not exceed 14.7 in normal subjects. Both catheter and
wireless pH monitoring allow quantiﬁcation of esophageal
acid exposure and assessment of the temporal relationship
between symptoms and acid reﬂux events [55]. Whether
the examination should be performed with the patient on
or oﬀ PPIs is still debated. Testing oﬀ-therapy is often
recommended for patients with a low index of suspision for
reﬂux disease, to rule out GERD. Thus, in a patient oﬀ PPIs
with normal pH study, the symptoms under consideration
are not attributable to reﬂux. On-therapy study is usually
used while patients are on PPIs twice daily, intending to
investigate the hypothesis of residual acid reﬂux [55, 56].
The threshold acid exposure time for an abnormal pH study
done on PPI therapy proposed to be lowered to the level
of 1.6% [57]. As the diagnostic yield of on PPIs study is
limited [58, 59], inclusion of symptom indices (symptom
index, symptom association probability) adds an important
dimensiontotheinterpretationofpHmonitoring.Whilethe
%t i m ep H> 4 indicates the presence of abnormal acid, the
symptom indices help to identify the causality of a particular
symptom with episodes of acid reﬂux regardless of whether
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A positive pH study on PPIs suggests that patients’ persistent
heartburn might be related to ongoing acid reﬂux (presence
of abnormal pH suggest insuﬃcient acid inhibition, whereas
positive symptom indices with normal pH suggest that
heartburn is induced by normal levels of acid exposure) [32,
56, 59, 60] .An e g a t i v ep Ht e s to nP P I sp r o v i d e sc o n v i n c i n g
evidence that the patients’ symptoms are not related to
ongoing acid reﬂux. However, a negative pH test on PPIs
doesnotexcludethepossibility ofunderlyingreﬂuxthatmay
be a cofactor in patient’s symptom and is being adequately
suppressed on PPIs. As the poor tolerability of pH probes
could result in a signiﬁcant decrease in reﬂux provoking
activities [61], the use of wireless pH capsule, that allows
combined testing both oﬀ and on PPIs, has been suggested
to improve the sensitivity of the pH test [55, 62].
In GERD patients who failed PPI twice daily, the use
of esophageal impedance-pH monitoring is a very promising
technique. Multichannel intraluminal impedance monitor-
ing with pH sensor (MII-pH) can detect all types of
reﬂux (acidic, weakly acidic, and weakly alkaline). This
test measures the resistance of electrical conductivity of
the esophageal content, thus detecting any change of the
esophageal pH due to the presence of liquid or gas reﬂux
[63, 64]. Moreover, with the inclusions of several channels,
it can detect the direction of bolus movement, thus allowing
identiﬁcation of swallows (anterograde) and reﬂux events
(retrograde) [63]. Therefore, it is superior to pH monitoring
in the detection of reﬂux symptoms associated with weakly
acidic or nonacid reﬂux in patients on PPI therapy [60,
65]. The test can also provide information regarding the
height of the reﬂux column inside the esophagus and the
association between symptoms and reﬂux episodes (using
symptom index or symptom association probability) [63].
Nevertheless, the use of an impedance catheter with gastric
pH sensor can be used to evaluate whether the gastric
acid secretion is suﬃciently suppressed by the medication.
Thus the most important clinical indication of MII-pH
monitoring is the evaluation of patients with persistent
symptoms despite PPI therapy [66, 67]. Indeed Mainie et
al. [65] and Zerbib et al. [32] showed that in almost 50%
of patients on therapy with PPIs twice daily, esophageal
symptoms during 24-hour combined MII-pH monitoring
were associated with persistent reﬂux. Although impedance-
pH monitoring is the most sensitive technique for detecting
all forms of gastroesophageal reﬂux, the usefulness of the
test in the clinical practice has to be addressed. Thus, it
is still unclear whether impedance-pH monitoring should
be performed on or oﬀ PPIs [68]. Moreover, analysis of
impedance-pH monitoring is based on symptom associ-
ations which have limitations such as sharp cut points,
multiple types (symptom index, symptom association prob-
ability) and uncertain time windows for analysis [69].
In addition, manual correction of reﬂux events, which is
time consuming, should be performed as the available
software tends to overestimate the number of reﬂux episodes
[70].
The chemical composition of the reﬂuxate could be
evaluated by using Bilitec which assess bile reﬂux with
bilirubin as the surrogate marker. Detection of bilirubin in
the reﬂuxate is indicative of duodenogastroesophageal reﬂux
(DGER). A recent study showed that a signiﬁcant number of
persistent symptoms occurred in association with bile reﬂux
as measured by Bilitec [71]. However, the limited availability
of the Bilitec and the dietary restrictions that patients should
follow during the test, make its future quite obscure.
Barium esophagogram should be considered primarily
in GERD patients that present with dysphagia [52]. The
externalanatomyoftheesophagusandtheproximalstomach
can be visualized with an esophagogram. This can also
show the type and size of an associated hiatal hernia. This
diagnostic tool is reasonably accurate in cases of severe
(98.7%) or moderate (86%) esophagitis, but it has a very low
accuracy with mild esophagitis (24.6%) [72–74]. Moreover,
reﬂux of barium during radiographic examination is only
positive in 25%–75% of symptomatic patients and is falsely
positive in almost 20% of normal controls [75].
The aforementioned diagnostic tests are mostly invasive,
costly and usually not readily available for the practicing
physicians. The proton-pump inhibitor (PPI) test is an
alternative noninvasive test for the diagnosis of GERD at the
disposal of every primary care physician. This test comprises
a short course of high-dose PPI (usually omeprazole) and
is used as a ﬁrst-line diagnostic strategy [52]. The notion
of the test is based on the hypothesis that if a patient
reports symptoms consistent with GERD and responds to
therapy with PPI, then he/she should have GERD. The
strategy of PPI test is not as robust at patients with non-
erosive reﬂux disease as it is in patients with esophagitis.
Indeed, a recent clinical review conﬁrms that the clinical
need for the PPI test increases as the true prevalence of
GERD in esophageal (erosive, non-erosive reﬂux disease,
non-cardiac chest pain) and extraesophageal syndromes
decreases. Recently, the Rome III committee suggested that
lack of response to full course of PPI is mandatory for the
diagnosis of functional heartburn [76]. They also recognized
that patients with a normal PPI test and endoscopy, but who
respond to PPI treatment should be considered as having
GERD.
A limitation of the test is that in a case of a negative
response the diagnostic utility of endoscopy is limited as
that the putative presence of mucosal injury, which is highly
speciﬁc for GERD, will likely be healed [49]. In addition,
none of the studies so far has determined if a positive
response to the PPI test may predict a long-term response
to medical treatment [52].
5. Treatment Approaches
Life style and dietary modiﬁcations, together with antacids
have long been the ﬁrst line of treatment. Decreased fat
intake, weight loss, cessation of smoking, elevation of the
head of the bed, and avoiding recumbency for 3 hours
postprandially, seem to decrease acid exposure of the lower
esophagus [77]. In addition, the avoidance of certain foods
such as coﬀee [78], chocolate, alcohol, peppermint, onions
and garlic, which are known to reduce LES pressure, seems
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the eﬃcacy of these measures, expert opinion holds that it
is reasonable to educate the patient about factors that may
precipitate reﬂux.
Antacids, alginic acid, and over-the-counter acid sup-
pressants are useful in the symptomatic relief of milder
f o r m so fG E R D[ 72, 73, 79]. In the past several trials
suggested that eﬀective symptom relief was obtained in
the majority of patients taking over-the-counter medication
[80, 81].
5.1. Acid Suppression for GERD. Histamine 2 receptor antag-
onists (H2RAs) were the acid suppression therapy of choice
from the mid-1970s until the introduction of proton pump
inhibitors (PPIs) into clinical practice in the late 1980s [82].
Currently several types of H2RAs-cimetidine, ranitidine,
famotidine, and nizatidine, are available over-the-counter.
These drugs in regular doses can decrease gastric acid
especially after a meal. H2RAs have a much longer duration
of action than antacids [73]. However, several drawbacks
limit the use of H2RAs in the treatment of GERD. They
are not eﬃcacious in the healing of severe esophagitis;
in addition, maintenance therapy with standard doses of
H2RAs cannot prevent relapses [83]. Today they are used
for the treatment of milder forms of the disease and
for on-demand therapy, especially for nocturnal symptoms
[84].
The class of PPIs is the most potent type of acid-
suppressive therapy. PPIs are substituted benzimidazoles
that irreversibly bind the H+K+—ATPase, the ﬁnal step in
gastric acid secretion [85]. Members of this group include
omeprazole, lansoprazole, pantoprazole, rabeprazole, and
esomeprazole. The standard doses of each drug type can
exert a similar acid inhibitory eﬀect. Omeprazole is the
agentwiththelongestdocumentedsafetyrecord,whereasthe
newest agents, rabeprazole and pantoprazole may interact
less than the other two with cytochome P450 metabolism
[86]. Several trials have shown the superiority of PPIs over
H2RAs in the treatment of reﬂux esophagitis. Klinkenberg-
Knol et al. [87]h a v ed o c u m e n t e de ﬀective long-term control
of GERD with PPIs, showing that long-term therapy with
omeprazole in regular doses (20 to 60mg/d) maintains
healing of esophagitis for up to 11 years. PPIs in standard
doses control symptoms in more than 80% of cases and
heal esophagitis in almost 90% of cases within a period
of 4–8 weeks [88]. A recent metanalysis in patients with
esophagitis showed that PPIs exhibit a better healing eﬀect
and faster symptom relief than histamine receptor antago-
nists (H2RAs), which are in turn better than placebo [89].
The success rate of esophagitis healing was 83% after 8 weeks
of therapy. Moreover, PPIs are eﬀective for maintenance of
esophagitis healing and symptom control in patients who
respond to an acute course of therapy for a period of 6–
12 months [49, 90]. Whether one PPI is superior to the
other is a matter of a matter of controversy. Although
data suggest diﬀerences among various PPIs with respect
to healing rates [91], absolute diﬀerences in eﬃcacy are
very modest and more pronounced in patients with severe
esophagitis [89]. However, individual variability in patient
responsetoPPIsvarieswidelyandinpatientsnotresponding
to one PPI switching to another one is usually recommended
[92].
Administartion of PPIs is not as robust at resolving
GERD symptoms in patients with negative endoscopy. Only
61% of patients experienced resolution of heartburn with
PPIs, which is still superior compared to 40% with H2RAs
administration [93, 94]. Thus, response of patients with
NERD to a standard dose of PPI is approximately 20%–30%
lower than that of patients with erosive esophagitis.
Inadequate symptom response to once-daily PPI therapy
aﬀects up to 40% of GERD patients and is the most common
issue faced by gastroenterologists [59]. The majority of these
patients originate from the group with NERD and functional
heartburn. In the setting of PPI failure, experts recommend
an escalation to twice-daily dosing of PPIs to improve
symptom relief [49]. However, identiﬁcation of the potential
mechanisms forlack to response to PPI should be considered
before the above mentioned therapeutic strategy. Putative
mechanisms for failure of PPI treatment include compliance,
improper dosing time, weakly acidic reﬂux, DGER, delayed
gastric emptying, esophageal hypersensitivity, eosinophilic
esophagitis nocturnal reﬂux, residual acid reﬂux reduced
PPI bioavailability, and psychological comorbidity [56, 95].
Compliance and dosing time should be assessed in all
patients prior to ordering any evaluative test. The optimal
timing for PPIs administration is 30 minutes prior to a
meal. Among the other mechanisms, most attention is
focused on weakly acidic reﬂux or DGER. In the presence
of weakly acidic reﬂux or DGER, esophageal hypersensitivity
to low-intensity reﬂux events is suggested as the underlying
mechanism for symptom generation [96, 97]. Thus, it is
clear that treatment success depends on identiﬁcation of
the putative mechanism of the PPI failure. In case of
residual acid reﬂux, increasing the PPI dose to twice daily,
switching to another PPI or adding H2RA mainly for
noncturnal reﬂux could oﬀer a successful therapy option
[98].
5.1.1. New Agents. New agents have recently emerged for
the treatment of patients nonrespondent to PPI treatment.
To address this clinical issue, research eﬀorts have focused
on “reﬂux inhibition”—that is, inhibition of transient lower
esophageal relaxations (TLESRs), the predominant mech-
anism of GERD. Thus the γ-aminobutyric acid (GABA)
type B (GABAB) receptor has emerged as one of the most
promising drug targets through which TLESRs can be
modulated [99]. Thus in patients with positive esophageal
impedance test for weakly acidic reﬂux, treatment with
baclofen, a GABA agonist, which reduces the rate of TLESRs,
should be considered. Due to the extensive side eﬀect
proﬁle of the drug, a low initial dose with a step-up
strategy is usually suggested. Another therapeutic option of
these patients, especially if the main resistant symptom is
regurgitation, is antireﬂux surgery. A recent study conﬁrmed
that patients who were refractory to PPIs and had positive
SI or SAP on esophageal impedance successfully underwent
laparoscopic Nissen fundoplication [100]. In patients with
negative esophageal impedance monitoring, visceral pain
modulators could be helpful [56, 98]. These agents (tricyclic6 Gastroenterology Research and Practice
antidepressants,trazodone,andselectiveserotoninereuptake
inhibitors), used in non-mood-altering doses, oﬀer their
visceral analgesic eﬀect by acting at the central nervous
system and/or sensory aﬀerents level. Promotility agents
(prokinetics) have been used in conjunction with PPIs
for the treatment of GERD [101]. However, very few of
these agents have been proven useful. Cisapride, a selective
agonist of 5-HT4 receptor has been used in the past for
the symptomatic treatment of nocturnal reﬂux, because it
could signiﬁcantly reduce TLESRs during sleep. However,
it has been abandoned due to its documented association
with fatal arrhythmias [102]. Tegaserod, a new selective
5-HT4 partial agonist is being used for the treatment of
irritable bowel syndrome and is under investigation for the
treatmentofGERD.Inarecentstudy thisdrugreducedpost-
prandial esophageal acid reﬂux episodes, although without
an apparent eﬀect on lower esophageal sphincter pressure
[103].
5.1.2.MaintenanceTherapy. GERDisachronicdisorderthat
often requires long-term maintenance therapy. Regardless
of endoscopic status at diagnosis, the majority of GERD
patients will experience relapse within six months of cessa-
tion of short-term acid suppression therapy. The strongest
data for maintenance therapy are for erosive esophagitis.
A recent meta-analysis showed that 75% of patients with
erosive esophagitis, who receive an acute treatment with
PPIs, would relapse after a period of 6–12 months without
maintenance therapy [104]. This review provides evidence
that PPIs are the most eﬀective therapy (versus H2RAs
and versus placebo) at maintaining remission in patients
with esophagitis—both in terms of endoscopic inﬂamma-
tion and symptom relief. Although H2RAs are inferior to
PPIs there may be a role for them with PPI-intolerant
patients.
In patients with NERD there are diﬀerert therapeutic
options: daily (continuous), intermittent ﬁxed courses, or
on-demand therapy. The role of daily maintenance therapy
in patients with NERD is less clear. The above-mentioned
review showed that PPIs are superior to placebo and H2-
RAs for controlling symptoms [104]. As the need for
maintenance therapy in patients with NERD is driven by
the impact of residual symptoms on their quality of life,
on-demand therapy (treatment only when symptoms occur)
could be a reasonable approach. Indeed, the proportion of
GERD patients that do not require a daily dose of acid
suppression to maintain symptom control is estimated to
be 20%–40% [105]. A systematic review showed that on-
demand therapy with currently available PPI appears to
be eﬀective in the long-term management of patients with
NERD or mild and uninvestigated forms of GERD, but not
in patients with erosive esophagitis [106]. Although PPIs are
more eﬀective overall, antacids or alginate-antacids were also
have a prominent role, as adjuvant, on-demand therapies
[107]. This was because both drugs have the ability to
provide a rapid and adequate relief from GERD symptoms;
they are most eﬀective once heartburn is already present,
whereas PPIs are more eﬀective in preventing heartburn
[49, 107].
A major concern of the long-term PPI therapy is the
potential side eﬀects that can aﬄict patients who have been
chronically treated with these drugs. At ﬁrst there was a
potential risk of atrophic gastritis and/or hypergastrinemia
induced carcinoid tumors due to hypochlorhydria. However,
these risks are slight if even demonstrable in clinical practice
settings[108].Nowadays,newconcernshavebeenidentiﬁed;
the most convincing data link PPI use with an increased
riskofClostridiumdiﬃcilecolitisandbacterialgastroenteritis
[108, 109]. With respect to the hip fracture, there is an
increased risk which seems to be of relatively low but
worthwhile magnitude [110]. The putative mechanism for
fracture is the decreased calcium absorption due to acid
inhibition [111]. It seems a good medical practice to screen
and treat the elderly for osteoporosis irrespective of PPI use
[49]. To summarize the available risk/beneﬁt data on PPIs,
PPIs should be used for appropriate indications and should
not be used in higher doses or for longer durations necessary
to achieve the desired outcome.
5.2. Surgery for GERD
5.2.1. Open Antireﬂux Surgery. Antireﬂux surgery has devel-
oped only after it was documented in the 1950s that a hiatal
hernia was associated with GERD [112]. At the beginning,
when hiatal hernia was considered the major factor in the
production of GERD, antireﬂux surgery was performed
to reduce the hiatal hernia and keep the LES within
the peritoneal cavity [113]. Later, when low LES pressure
was considered the major factor in the incompetence of
the gastroesophageal junction, antireﬂux procedures were
performed to increase LES pressure [114]. Fundoplication
was ﬁrst introduced by Nissen in 1956, after the incidental
observation that a fundal patch used to reinforce the
esophageal suture line could also correct gastro-esophageal
reﬂux. In the following years, the Belsey and Toupet [115]
(partial wrap, 180–200◦) procedure has been applied for
the treatment of GERD. Despite this relatively short history,
antireﬂux surgery techniques have been gradually advanced
overtime resulting in gradual improvement in the clinical
outcome [114, 116].
As of today, given that transient LES relaxation (TLESR)
is the main mechanism responsible for GERD, the aim
of surgery is to lengthen the intraabdominal portion of
the LES, to reduce the volume of the gastric fundus and
prevent eﬀacing of the LES during distention of the stomach
postprandially [117].
Following four decades of treatment with open antire-
ﬂux procedures, the long-term clinical outcome after open
surgeryhasbeenwelldescribed.DeMeesteretal.[13],aswell
as other authors [118, 119], have reported a 90% long-term
reﬂux control after Nissen fundoplication.
Aftertotalfundicwrapseveraladverseconsequencesmay
occur; these include persistent dysphagia, inability to belch
and vomit, epigastric fullness, bloating and pain postpran-
dially, temporary swallowing discomfort, and sometimes
intense ﬂatus [120]. Many of these postfundoplication
side-eﬀects have been included under the term “gas bloat
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is an increase in LOS tone after these procedures more
prominent after total fundoplication [121] .T h er i s ei nt h e
sphincterpressureoccurswhentheloweresophagusisplaced
in the intra-abdominal position, where it is in a positive
pressure environment [122]. A possible explanation could
be that total fundoplication may overcorrect the mechanical
deﬁciency in the gastroesophageal junction, creating a super-
competent cardia [123].
On the other hand several studies have demonstrated
that these operations reduce the hiatal hernia and restore
the physiology of the gastroesophageal junction to normal.
Nissen fundoplication reduces postprandial reﬂux by aﬀect-
ing the frequency of TLOSR. Furthermore, these operations
render swallowing-induced LES relaxation incomplete by
compressing mechanically the LES segment [120, 123].
Toupet fundoplication only encircles half of the esophageal
circumference and thus the basal LES sphincter tone is
signiﬁcantly lower than in Nissen procedure [121]. This
procedure normalizes LES tone, without impairing the
ability of the LES to relax on proper stimulation [124].
Moreover, it seems to maintain the same high level of
reﬂux control as Nissen procedure. It has been shown
that patients after the Toupet procedure have less trou-
blesome ﬂatus and maintain their ability to belch, with-
out jeopardizing important reﬂux-preventing mechanisms
[120, 125].
In the past it has been supported that patients with
pooresophagealmotility(distalesophagealbodycontraction
amplitude <30mmHg) be treated with a partial fundo-
plication rather than a total one, to avoid the side eﬀect
of the latter. However, this idea was not supported by
the results of a randomized clinical trial [126]. There
are clinical advantages in doing a Toupet procedure, but
there are also some technical modiﬁcations of the Nissen
procedure which help in minimizing these side-eﬀects [127,
128]. The preferred and most eﬃcient modiﬁcation of
the Nissen fundoplication is the short “ﬂoppy” Nissen
fundoplication, which has been shown to have success
rates of up to 90% with minimal morbidity and mortal-
ity.
Patients with Barrett’s esophagus usually suﬀer from
severe GERD, and antireﬂux operations oﬀer potential
advantages by restoring the LES pressure and abolishing
gastric or alkaline reﬂux into the esophagus [129]. The
eﬀect of antireﬂux surgery on the natural history of Barrett’s
esophagus is a matter of controversy. Several studies doc-
ument the eﬃciency of surgical therapy in the prevention
of intestinal metaplasia in GERD patients[129, 130]. Others
did not document any regression of intestinal metaplasia
after antireﬂux procedures [131, 132]. Despite the fact that
complete regression rarely occurs, regression of the length
of Barrett’s epithelium is commonly observed [130, 133].
Furthermore, disease progression, after antireﬂux operation,
to severe dysplasia or adenocarcinoma occurs in a reduced
incidence compared with medical therapy [129]. This is
explained by the fact that fundoplication creates a new
antireﬂux valve, which prevents both acid and bile reﬂux,
a prerequisite for the development of Barrett’s esophagus
[134].
5.2.2. Laparoscopic Surgery. Over the last ﬁfteen years the
advent of laparoscopic surgery has changed the way in
which antireﬂux surgery is performed, with the associ-
ated advantages of minimally invasive surgery, rendering
esophageal wrapping more acceptable. Despite the fact that
open surgery for GERD was reserved for patients with
severe symptomatology or complications, the introduction
of laparoscopy in the management of the disease has resulted
in a trend to operate at an earlier stage [135]. The ﬁrst series
of laparoscopic fundoplication was ﬁrst reported in 1991, by
Geagea from Canada [136], and Dallemagne from Belgium
[137].Sincethen,thisoperationhasspreadallovertheworld
and was introduced in the routine clinical practice as the
preferred surgical treatment for GERD. The advantages of
this technique are reduced pain, less surgical trauma, shorter
hospital stay, and better cosmetic result. Several studies
have reported excellent short term results for this procedure
[114, 116, 138]. However, other reports have emphasized
the high incidence of early postoperative complications,
such as the paraesophageal migration of the wrap or the
stomach [139, 140]. With increasing experience, mortality
after laparoscopic Nissen fundoplication has been reported
to be very limited, not exceeding 0.1%. However, patients
have to get used to several side eﬀects, such as inability to
vomitortobelch,and/ormechanicalobstructionoftheswal-
lowed bolus, due to the wrap construction [141]. Moreover,
dysphagia of suﬃcient severity to require esophageal dilation
takes place in about 6% of patients after antireﬂux surgery
[142, 143]. A recent randomized clinical trial suggests that
laparoscopic Nissen fundoplication is associated with more
obstructivecomplaintsintheearlypostoperativeperiodthan
the open approach [142]. However, this has not been recon-
ﬁrmed by other authors [144]. There is a consensus among
laparoscopic surgeons that the Nissen ﬂap has to be both
short and ﬂoppy to avoid early dysphagia [141]. Regarding
long-term clinical outcome, the laparoscopic approach oﬀers
good to excellent results after a follow-up period longer
than 5 years; however, there is still a possibility of technical
failure, and the reoperation rate varies between 4% and
13% [145]. Dallemagne et al. [146] reported that 90% of
a group of patients had symptom control 10 years after
surgery, and that less than 10% of patients had to resume
medication again. They also observed more recurrences after
partial posterior fundoplication (Toupet) than after Nissen
fundoplication. On the other hand, recurrent reﬂux after a
Nissen fundoplication may often require a redo operation
because of the accompanying dysphagia. In cases with severe
persistent dysphagia, Nissen fundoplication should be taken
down and changed to a Toupet procedure [147, 148].
Persistent dysphagia due to a very tight wrap, wrap
disruption, incorrect placement and slippage of the wrap
are causes of failure and require reoperation [149]. Early
identiﬁcation of these problems may urge to laparoscopic
revision. However, later identiﬁcation, beyond the ﬁrst
postoperative week, often requires more extensive open
procedures. Experienced surgeons may perform revisions
laparoscopically, even months after the initial procedure
[150]. At revision, complete reduction of the previous
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performed. Symptomatic improvement is observed in the
majority of patients after revisional surgery for dysphagia.
Laparoscopic revision is technically demanding but can
produce satisfactory results similar to these of the initial
operation [151].
Another issue is based on the observation that patients
with Barrett’s esophagus who have undergone a fundoplica-
tion, which has subsequently failed, are at increased risk of
developing esophageal cancer during long-term follow up,
due to recurrent reﬂux. For that reason if the fundoplication
has failed, the patients should resume PPI medication until a
laparoscopic revision is performed [134].
Laparoscopic fundoplication has replaced the open
approachinmostcenters,beingmoreacceptablebysurgeons
and patients. This approach can eﬀectively control GERD
symptoms and improve quality of life even in patients with
recalcitrant GERD [151]. The laparoscopic approach has
also been proven equally eﬀective as the open approach
in controlling GERD symptoms. Although the dysphagia
rate after both procedures is similar, the open approach
has a higher incidence of postoperative chest and wound
complications. Moreover, the incidence of temporary gastric
fullness and bloating syndrome is higher with the open
approach [152]. In general, laparoscopic fundoplication is
a na c c u r a t ep r o c e d u r ew i t ha na c c e p t a b l ec o m p l i c a t i o nr a t e
and easily accessible to the general surgeon. Physicians
and surgeons are now not reluctant to refer for or to
perform laparoscopic fundoplication at least in selected
patients.
5.2.3. Endoluminal Surgery. The last few years novel endo-
scopic techniques have been introduced for the treatment of
GERD. Endoluminal gastroplication (ELGP) was the ﬁrst of
the proposed endoscopic treatments for GERD. EndoCinch
(C.R. Bard Inc., Cranston, RI), a commercially available
suturing system has been used for ELGP. The eﬀectiveness of
this system has been proved in multicenter trials in the West
[153], and also in Japan [154]. The procedure was found
to be safe and was eﬀective in about 60% of patients with
GERD [155]. However, it failed to normalize acid reﬂux,
had some serious complications, and long-term durability
data are lacking [156]. Another technique using the Plicator
device (NDO Surgical, Inc., Mansﬁeld, MA) has been widely
used. This technique mimics the eﬀects of antireﬂux surgery
by recreating the antireﬂux barrier, restoring the angle of
Hiss and forming an one-way gastroesophageal valve. The
Plicator procedure has been tried in several centers and has
been shown to reduce GERD symptoms and medication use
for at least 36 months following initial treatment [155, 157].
Moreover, this procedure is free of major complications and
generally well tolerated [157].
A more practical technique, the novel endoluminal
fundoplication (ELF) technique has been introduced to
overcome some of the Plicator’s disadvantages, such as
the inability to reduce hiatal hernia and create a robust
gastroesophageal valve. According to the ELF technique, the
gastroesophageal valve is created from the inside of the
stomachviatransoralaccess.TheEsophyxXTM device(Endo-
gastric Solutions, Inc., Redmond, WA, USA) is introduced
trasnorally to create a full thickness omega shaped valve
3–5cm in length and 200–300◦ in circumference through
delivery of multiple fasteners under endoscopic visualization
[158]. This new technique results in the creation of robust
and durable gastroesophageal valve, which improves the
functionality of the antireﬂux barrier. A multicenter study is
underway in Europe to assess the long-term eﬃcacy of the
ELF procedure [159].
5.3. Medical versus Surgical Treatment for GERD. Surgical
treatment for GERD has previously been limited to cases
with chronic complicated reﬂux and severe symptomatology
not responding to medication. Today there is increased
tendency worldwide to utilize surgery in the earlier stages of
the disease [160]. This change in clinical practice is mainly
due to advancements in surgical technique, the increased
patient satisfaction by laparoscopy, and the increased aware-
ness of the impairment in quality of life of patients who
are not eﬃciently treated [161]. Moreover, the increasing
enthusiasm of patients and surgeons for minimally invasive
surgery has led to the wider application of laparoscopy in
the management of GERD in many institutes worldwide.
Although modern drug therapy is very eﬀective in the long-
term management of GERD, antireﬂux surgery seems to be
more cost eﬀective than medical therapy and safer regarding
long-term eﬀects of acid suppression and development of
adenocarcinoma of the esophagus in patients with severe
forms of the disease [162].
There are several trials favoring the clinical outcome
of laparoscopic antireﬂux surgery compared to long-term
PPI therapy. A large randomized clinical trial from the
UK has shown signiﬁcantly better physiological control of
reﬂux in patients having undergone laparoscopic Nissen
fundoplicationthanpatientsundermaintenancePPItherapy
[163]. There was also better general well being in the surgery
group after a followup of 12 months. Nevertheless, a recent
prospective study on laparoscopic Nissen fundoplication
from J. Hunter’s group from Atlanta [164] with an 11-year
mean follow up, demonstrated a signiﬁcant symptom con-
trol, increased patient satisfaction, and complete withdrawal
of antireﬂux medications by 70% of patients. This represents
strong evidence regarding the eﬃcacy and durability of the
laparoscopic approach. In addition, a recent prospective
trial from the UK [165] comparing laparoscopic Nissen
fundoplication with PPI therapy, with 7-year follow-up,
demonstrated that all patients, no matter the type of therapy,
had a signiﬁcant symptom improvement after the initial 12
months; however, patients who underwent surgery despite
having had optimal PPI treatment had further symptomatic
improvement at long-term follow-up.
However, other authors report modest results after
laparoscopic antireﬂux surgery. Balsara et al. [166]f r o m
India analyzed retrospectively their experience with laparo-
scopic fundoplication over an 8-year period. This operation
was performed in 84 patients, and 74 of them had been
followed up for a period of 7 months to 8 years. Of these
patients 57 (77%) have had a good result from surgery.
Seventeen (23%) had a poor result, due to wrap failures,
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individual variables predicting a good response to surgery,
including a good response to PPIs, volume reﬂux, and a pH
score of more than 14. They concluded that strict selection
criteria are necessary to optimize the results of surgery. Poor
selection may result in a patient who may not beneﬁt from
surgery, but may be worse than before surgery.
In addition other studies challenge the superiority of
antireﬂux surgery in the treatment of esophagitis. Thus,
Lundell et al. [167] have reported 5- and 7-year results of
a randomized controlled trial of patients with esophagitis
treated with omeprazole or surgery. At 7 years the two
treatments were similar regarding the incidence of recurrent
esophagitis (10.3% omeprazole versus 11.8% antireﬂux
surgery). In addition the two therapies appeared to be
equivalent in healing esophageal mucosa.
Conﬂicting evidence also exists regarding the eﬃcacy of
antireﬂux surgery in case of Barrett’s esophagus. Previous
reports support laparoscopic antireﬂux surgery as the most
eﬀective treatment for Barrett’s esophagus, as it provides
a durable reﬂux barrier, stimulates regression of intestinal
metaplasia, and reduces the risk of adenocarcinoma [168].
However, a recent meta-analysis [169]f a i l st op r o v ea n y
protective eﬀect of surgery against esophageal cancer.
Although the superiority of surgery to PPI therapy
regarding the symptomatic control of reﬂux is well rec-
ognized, there are no controlled data comparing the two
treatments with respect to the extraesophageal syndromes.
However, observational studies show some beneﬁt with
surgical treatment for highly selected patients with reﬂux
cough syndrome [170] and reﬂux asthma syndrome [171].
As for the recently evolving endoluminal therapy, there
are no studies comparing the eﬃcacy of these devises with
either medical therapy of antireﬂux surgery. According to
some authors the plicator procedure could be a treatment
option for patients with mild symptomatic GERD who do
not wish to remain on PPIs and who do not currently
wish to undergo surgical therapy [157]. However, due to the
small numbers and the short follow up of these preliminary
studies on endoluminal therapy in GERD [172], it is too
early to draw conclusions for its eﬃcacy and long-term
outcome.
6. Conlusions
GERD is a very common disease with a broad spectrum
of clinical symptoms and disorders. From a therapeutic
perspective, GERD results from reﬂux of gastric contents
into esophagus due to mechanisms including TLESRs and
hiatal hernia. For diagnosis, PPI test is advocated as a simple
diagnostic tool to identify patients with GERD. In cases with
high likelihood of GERD and a negative PPI test, the best
method to diagnose reﬂux is the 24-hour pH test alone or
in combination with impedance.
PPIs are considered the best therapeutic option for the
initial treatment of GERD patients. Symptomatic relapse is
very frequent; therefore, most patients need a long-term
treatment. The goals of an eﬀective maintenance therapy
are control of symptoms and prevention of complication.
Medical and surgical treatments options are both eﬀective
as maintenance therapies. PPIs are the mainstay of medical
long-term treatment. In patients with severe esophagitis,
continuous PPI therapy with the lowest eﬀective code based
on symptom control is the appropriate long-term strategy.
On-demand therapy is the reasonable strategy in the long-
term management of patients with NERD.
Choosing the right candidates for surgery still remains a
problem. Usually young patients who are willing to get rid of
long-term maintenance medication are the best candidates
for surgery. Also patients who are refractory to medical
treatment, especially those with nocturnal regurgitation, and
young patients with recurrent peptic strictures may beneﬁt
from surgery. Another important factor in determining the
outcome of antireﬂux surgery is the surgeon’s experience. It
has been shown that low volume centers yield much poorer
outcomes.
The choice of the treatment schedule should always be
individualized for every patient. It is therefore up to the
patient, the physician and the surgeon to decide which the
best treatment option is. Medical and surgical therapies
for the GERD are not competing or they are not even
complementary. They are probably the two sides of the same
coin.
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